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EDITORIAL
On and Off: A Dual Role for Cysteine Protease
Autoprocessing of C difficile Toxin B on Cytotoxicity
vs Proinﬂammatory Toxin Actions?
Clostridium difﬁcile is the leading bacterial cause ofhealth care–associated diarrhea in the developed
world. In recent years, there has been an alarming increase
in the incidence and severity of Clostridium difﬁcile in-
fections (CDIs), leading to increased academic, public health,
and drug development research efforts on this bacterium.
Two major virulence factors of C difﬁcile are its toxin A
(TcdA) and toxin B (TcdB). Understanding the mechanisms
of action of these toxins is important to advance knowledge
of CDI pathogenesis and identify new targets for prevention
and therapy.
TcdB, similar to TcdA, is a large single-chain protein
that contains at least 4 distinct domains: the N-terminal
glucosyltransferase enzymatic domain (GTD), cysteine
protease enzyme domain (CPD), a putative translocation
domain, and a C-terminal receptor binding domain. After
receptor-mediated endocytosis and/or alternative entry
pathways, the translocation domain mediates trans-
location of the CPD and GTD enzymatic regions into the
cytosol where CPD self-cleaves in the presence of Inositol
hexakisphosphate and releases GTD from the rest of the
toxin.1 GTD inactivates Rho guanosine triphosphatases,
which are key cell signaling molecules, leading to cyto-
toxicity. Thus, CPD plays a key role in the cytosolic de-
livery of GTD to turn on cytotoxicity.
The proinﬂammatory activities of TcdB in human colon
tissues and monocytes are well documented. Inactivation of
RhoA results in the stimulation of the pyrin/apoptosis-
associated speck-like protein containing a caspase recruit-
ment domain inﬂammasome,2 which is one of the main
signaling pathways used by these toxins to trigger the in-
ﬂammatory response. However, the relationship between
toxin’s cytotoxicity and proinﬂammatory activity has
remained elusive. Although GTD-deﬁcient toxins failed to
induce acute intestinal responses in a number of studies,3,4
indicating an essential role of GTD, there also have been
reports suggesting that GTD is not required for the induced
proinﬂammatory response of TcdB.5
In a new study in the current issue, Zhang et al6 made
the novel and exciting observation that the CPD auto-
processing activity of TcdB acts as an off switch for
proinﬂammatory activity and an on switch for cytotox-
icity. By analyzing inﬂammatory responses in mouse ilea
loops, human tissues, and immune cells, they found that
blocking autoprocessing of TcdB by mutagenesis or
chemical inhibition resulted in reduced cytotoxicity of the
toxin, but surprisingly enhanced its proinﬂammatory ac-
tivities in a ligated mouse ileal loop model. Zhang et al6
further validated in ex vivo human colonic tissues and
immune cells that a noncleavable mutant TcdB was
signiﬁcantly more potent than the wild-type toxin in the
induction of proinﬂammatory cytokines.
This study suggests a dual role of CPD-mediated
autoprocessing, which regulates the relative outcomes of
cytotoxicity and proinﬂammatory induction. There have
been suggestions that CPD inhibition could trap TcdB in the
endosome, thereby mitigating cytotoxic effects. However,
this study suggests that there may be an unintended
consequence to CPD inhibition in the form of increased in-
ﬂammatory pathway activation. The question remains,
however, which of the 2 components, cytotoxicity or
proinﬂammatory responses, contribute more to disease
pathogenesis.
The investigators showed that autocatalytic processing-
deﬁcient TcdA or TcdB mutants still have some cytotoxic
activity, but at a reduced level compared with wild-type
toxins. However, the proinﬂammatory activity was
enhanced signiﬁcantly. This may have alarming implications
for drug development using CPD as targets. This study did
not use infectious murine models of CDI, but it should be
noted that in vivo studies in such models have found that
CPD inhibitors reduced the overall severity of CDI.7,8
Moreover, TcdB from hypervirulent C difﬁcile shows
increased autoprocessing efﬁciency.9
Although this study opens up many questions, it pro-
vides a new component of C difﬁcile toxin mechanism of
action, particularly in understanding how endosomal teth-
ering, GTD domain localization, and/or release impact the
inﬂammatory response. As such, it exposes a new and
fascinating aspect to our understanding of the virulence of
this difﬁcult bacterium.
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